Design, Synthesis, and Biological Evaluation of New Cyclic Melanotropin Peptide Analogues Selective for the Human Melanocortin-4 Receptor
Authors:
- 19 October 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (23) , 6888-6896
Abstract
Intensive efforts have been made to develop potent and selective ligands for certain human melanocortin receptors as possible treatments for obesity and sexual dysfunction due to the role of these receptors in feeding behavior, energy homeostasis, sexual function, etc. A number of novel α-MSH analogues were designed and synthesized primarily on the basis of our previous MTII NMR structure. In these peptide analogues, a disulfide or lactam bridge between residues at positions 5 and 8 was used as a conformational constraint to enhance the β-turn spanning His6 and d-Phe7, while the pharmacophore group in Arg8 was mimicked via Nα-alkylation of residues 8 or 9 with the guanidinylbutyl group. Biological assays for binding affinities and adenylate cyclase activities for the hMC1R, hMC3R, hMC4R, and hMC5R showed that three analogues have good binding affinity for the hMC4R (0.7−4.1 nM), but have no binding affinity up to 10 μM at the other three melanocortin receptors. Interestingly, the three hMC4R selective analogues display only 50% binding efficiency, suggesting there is allosteric modulation of the melanocortin-4 receptor. These analogues were found to act as antagonists of the hMC4R. This result represents a discovery of very selective peptide-based antagonists for the hMC4R. The high selectivity may be due to the strong conformational constraint via ring contraction as compared to MTII, and the rigid conformation preferred by these new ligands allows them to recognize only the hMC4R, but not to activate the second messenger. The MTII NMR structure-based design thus not only examined the structural model of melanocortin ligands, but also yielded new biologically unique α-MSH analogues.Keywords
This publication has 47 references indexed in Scilit:
- New Concepts in Drug Discovery: Collateral Efficacy and Permissive AntagonismNature Reviews Drug Discovery, 2005
- Novel 3D Pharmacophore of α-MSH/γ-MSH Hybrids Leads to Selective Human MC1R and MC3R AnaloguesJournal of Medicinal Chemistry, 2004
- Structure−Activity Studies of the Melanocortin Peptides: Discovery of Potent and Selective Affinity Antagonists for thehMC3 andhMC4 ReceptorsJournal of Medicinal Chemistry, 2002
- Preparation of ‘side‐chain‐to‐side‐chain’ cyclic peptides by Allyl and Alloc strategy: potential for library synthesisChemical Biology & Drug Design, 2001
- Selective Antagonist for the Melanocortin 4 Receptor (HS014) Increases Food Intake in Free-Feeding RatsBiochemical and Biophysical Research Communications, 1998
- Semianalytical treatment of solvation for molecular mechanics and dynamicsJournal of the American Chemical Society, 1990
- Design of a new class of superpotent cyclic .alpha.-melanotropins based on quenched dynamic simulationsJournal of the American Chemical Society, 1989
- α-melanotropin: The minimal active sequence in the lizard skin bioassayGeneral and Comparative Endocrinology, 1989
- Conformational restrictions of biologically active peptides via amino acid side chain groupsLife Sciences, 1982
- Highly active cyclic and bicyclic somatostatin analogues of reduced ring sizeNature, 1979